Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection
Lexicon Pharmaceuticals
ISIN: US5288723027, WKN: A14SSK
Market price: 8,51 USD
Lexicon Pharmaceuticals Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 14-03-2020 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 113.807.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -70.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 113.737.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 117.101.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 417.715.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 130.133.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 1,110 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 117.237.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 322.070.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | LXRX |
| Market Capitalization | 994.169.728,00 USD |
| Country | United States |
| Indices | NASDAQ Comp. |
| Sectors | Pharma |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2015-05-21,1.0000/7.0000 |
| Internet | www.lexgen.com |
Description of the company
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.